Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III panitumumab trial in head and neck cancer does not meet primary endpoint

Aug. 13, 2010

University of Ulsan identifies new anticancer prodrugs

Aug. 13, 2010

Biotest updates development program for BT-062 in multiple myeloma

Aug. 12, 2010

ACT and Brown Cancer Center collaborate to identify cancer therapeutics

Aug. 12, 2010

Herceptin approved in Canada for HER2-positive stomach cancer

Aug. 12, 2010

Algeta begins phase I/IIa trial of Alpharadin/docetaxel combination in CRPC

Aug. 12, 2010

Hybrigenics presents new USP7 inhibitors

Aug. 12, 2010

Lentigen receives NIH grant to develop melanoma immunotherapy

Aug. 11, 2010

New alpha-mannosidase inhibitors identified by Emory University

Aug. 11, 2010

Daiichi Sankyo claims new Mdm2-p53 interaction inhibitors

Aug. 11, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...